Explore

Trendline Trendline
Puma Biotechnology Raises 2026 Revenue Guidance Amid Increased Demand for NERLYNX

Puma Biotechnology Raises 2026 Revenue Guidance Amid Increased Demand for NERLYNX

Puma Biotechnology Raises 2026 Revenue Guidance Amid Increased Demand for NERLYNX
Trendline Trendline
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Trendline Trendline
Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline

Rocket Pharmaceuticals Reports Financial Results and Advances Gene Therapy Pipeline
Trendline Trendline
Soligenix Reports Financial Results and Updates on Clinical Trials

Soligenix Reports Financial Results and Updates on Clinical Trials

Soligenix Reports Financial Results and Updates on Clinical Trials
Trendline Trendline
Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate

Nektar Therapeutics Strengthens Financial Position Amidst Development of Lead Biologic Candidate
Trendline Trendline
Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials

Verastem Oncology Reports $18.7 Million Revenue in Q1 2026 Amid New Clinical Trials
Trendline Trendline
Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges
Trendline Trendline
BioLife Solutions Reports 25% Revenue Growth in Q1 2026, Driven by Cell and Gene Therapy Market

BioLife Solutions Reports 25% Revenue Growth in Q1 2026, Driven by Cell and Gene Therapy Market

BioLife Solutions Reports 25% Revenue Growth in Q1 2026, Driven by Cell and Gene Therapy Market
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges
Trendline Trendline
Zura Bio Reports Strong Financial Position and Progress in Clinical Trials

Zura Bio Reports Strong Financial Position and Progress in Clinical Trials

Zura Bio Reports Strong Financial Position and Progress in Clinical Trials
Trendline Trendline
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum